AgomAb Therapeutics NV (AGMB) Fair Value 2026

AGMB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, AgomAb Therapeutics NV (AGMB) trades at $13.17. QOC: 3.6/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
AGMB
Price
$13.17
Quality Score
3.6/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.6/10 signals weak fundamentals

What Fair Value Does Each Model Give AGMB?

0 Intrinsic Value Models vs. Current Price ($13.17)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is AgomAb Therapeutics NV (AGMB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, AgomAb Therapeutics NV currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About AGMB?

0 of 13 models are currently active for AGMB. See which stocks rank higher →

How Does AGMB Rank in Biotechnology?

Among 625 Biotechnology stocks, AGMB ranks #568 by Quality of Company score. CirclFi's QOC score of 3.6/10 evaluates 32 fundamental signals. A score of 3.6 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, AgomAb Therapeutics NV operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating AGMB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is AGMB a Value Trap?

CirclFi's Value Trap algorithm assigns AGMB a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for AgomAb Therapeutics NV. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, AgomAb Therapeutics NV's fundamental quality profile registers 3.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AGMB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AgomAb Therapeutics NV Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ODTXOdyssey Therapeutics, Inc.QOC 3.6CNBXCNBX Pharmaceuticals Inc.QOC 3.6HEPAHepion Pharmaceuticals, Inc.QOC 3.6AKTSAktis Oncology, Inc.QOC 3.5ALZNAlzamend Neuro, Inc.QOC 3.7LNAILunai Bioworks Inc.QOC 3.5RAREUltragenyx Pharmaceutical Inc.QOC 6.4IFRXInflaRx N.V.QOC 5.3OTLKOutlook Therapeutics, Inc.QOC 4.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ODTX · CNBX · HEPA · AKTS · ALZN · LNAI · RARE · IFRX · OTLK · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AGMB?

5 companies across all industries closest to AGMB’s Quality of Company score of 3.6/10.

GIBOGIBO Holdings LimitedQOC 3.6AGLYAtlantis Glory Inc.QOC 3.6TXRPTX Rail Products, IncQOC 3.5PNSBPSB Financial, Inc.QOC 3.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GIBO · AGLY · TXRP · PNSB · NVDA

Where Does AGMB Sit in CirclFi's Biotechnology Rankings?

AGMB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About AgomAb Therapeutics NV’s Valuation?

What is AgomAb Therapeutics NV's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for AgomAb Therapeutics NV (AGMB). The Quality of Company score is 3.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AGMB overvalued or undervalued right now?

At $13.17, 0 of 0 active models suggest AGMB may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits AgomAb Therapeutics NV's business model in Biotechnology.

What does a Quality of Company score of 3.6 mean for AGMB?

AgomAb Therapeutics NV's QOC of 3.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on AGMB?

CirclFi analyzes AGMB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is AGMB a value trap in 2026?

AgomAb Therapeutics NV's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns AgomAb Therapeutics NV (AGMB) a Quality of Company score of 3.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/AGMB/ · Methodology
Primary sources for this AGMB valuation
  • Financial statements: AgomAb Therapeutics NV 10-K and 10-Q filings on SEC EDGAR (CIK 0002020932) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AGMB as of ; valuations recomputed .